Fig. 1From: Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitorsStudy flow diagramEGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitorBack to article page